1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class, By Region And Segment Forecasts, 2019 - 2026

Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class, By Region And Segment Forecasts, 2019 - 2026

  • April 2019
  • 122 pages
  • ID: 5778940
  • Format: PDF
  • By Grand View Research

Summary

Table of Contents

Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class (Prostacyclin & Prostacyclin Analogs, SGC Stimulators, ERA, PDE-5), By Region, And Segment Forecasts, 2019 - 2026

The global pulmonary arterial hypertension market size is expected to reach USD 9.3 billion by 2026. It is projected to progress at a CAGR of 5.6% during the forecast period. Increasing prevalence of Pulmonary Arterial Hypertension (PAH) and government support for the development of orphan drugs are fueling the growth.

The cases of PAH are rising in the range of 100,000 to 200,000 per year.However, in the past few years, the occurrence of this disorder has intensified due to the risk factors such as alcohol/tobacco consumption, HIV, sedentary lifestyle, smoking, and other idiopathic conditions.

Presence of a large geriatric population, with lower levels of immunity and prone to PAH and associated diseases, is a high impact-rendering driver for the PAH market. Though the beginning age for PAH is 45 years, it is often observed to occur in the population over 60 years of age.

Government initiatives, such as the Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983 are also anticipated to support market growth.These are the two most vital acts that promote the ethical usage and distribution of orphan drugs.

Development of orphan drugs is promoted by the National Organization of Rare Disorders and have a smaller market share.

Further key findings from the study suggest:
• Based on drug class, prostacyclin and its analogs are projected to witness lucrative growth over the forecast period. The sales of these drugs are anticipated to grow sharply, primarily due to the expected growth in oral prostacyclin agents
• North America held the leading market share of 58.3% in terms of revenue in 2018, attributed to supportive infrastructure for the development and distribution of high-quality therapies. Moreover, availability of reimbursement on PAH therapies supported the growth
• Asia Pacific is anticipated to expand at the fastest CAGR of 6.7% over the forecast period due to its huge population base, rapid economic developments, and improving healthcare systems. Besides, high burden of diseases such as HIV that are responsible for the development of PAH foster the regional market growth
• Major players operating in the pulmonary arterial hypertension market include GlaxoSmithKline Plc.; Actelion Pharmaceuticals, Ltd.; United Therapeutics Corporation; Pfizer, Inc.; and Gilead Sciences, Inc. The market is consolidated and competitive in nature. Companies enjoy the benefit of barrier in the entry to other firms due to high price interdependency.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Point of Care Diagnostics Market by Product, Platform, Mode, End-User - Global Forecast to 2024

Point of Care Diagnostics Market by Product, Platform, Mode, End-User - Global Forecast to 2024

  • $ 4950
  • November 2019

The point-of-care diagnostics market is projected to grow at a CAGR of 10.4% from 2019 to 2024.The global point-of-care diagnostics market is projected to reach USD 46.7 billion by 2024 from USD 28.5 billion ...

Reproductive Hormones and Proteins Tests - Medical Devices Pipeline Assessment, 2019

Reproductive Hormones and Proteins Tests - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • December 2019

Reproductive Hormones and Proteins Tests - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, “Reproductive Hormones and Proteins Tests - Medical Devices Pipeline Assessment, ...

Cardiac Markers Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019

Cardiac Markers Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • December 2019

Cardiac Markers Rapid Tests & Point of Care (POC) - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, “Cardiac Markers Rapid Tests & Point of Care (POC) - Medical Devices ...


ref:plp2019

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on